Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

6.25EUR
11 Oct 2019
Change (% chg)

€0.01 (+0.16%)
Prev Close
€6.24
Open
€6.27
Day's High
€6.39
Day's Low
€6.21
Volume
78,346
Avg. Vol
148,362
52-wk High
€12.52
52-wk Low
€5.40

Latest Key Developments (Source: Significant Developments)

Biocartis: 5 Idylla Performance Studies To Be Presented At Congress
Monday, 23 Sep 2019 

Sept 23 (Reuters) - BIOCARTIS GROUP NV ::FIVE IDYLLA PERFORMANCE STUDIES TO BE PRESENTED AT ‘EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY’ CONGRESS.ALL STUDIES DEMONSTRATED EXCELLENT PERFORMANCE OF IDYLLA COMPARED TO OTHER METHODS, IN COMBINATION WITH EASE OF USE AND FAST TURNAROUND TIME OF THE IDYLLA PLATFORM.LAUNCH OF FULLY AUTOMATED IDYLLA CTEGFR MUTATION ASSAY FOR LIQUID BIOPSY TESTING OF EGFR MUTATIONS IS EXPECTED IN Q4 2019.  Full Article

Biocartis: Final Terms Of EUR 150 Million Senior Unsecured Convertible Bonds
Thursday, 2 May 2019 

May 2 (Reuters) - BIOCARTIS GROUP NV ::INITIAL PRICE FOR CONVERSION OF BONDS INTO SHARES OF COMPANY SHALL BE EUR 12.8913.  Full Article

Biocartis Announces Commercialization Agreement With Covance
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Biocartis Group NV ::ANNOUNCES GLOBAL STRATEGIC COMMERCIALIZATION AGREEMENT WITH COVANCE, LABCORP'S DRUG DEVELOPMENT BUSINESS.AGREEMENT AIMS AT OFFERING IDYLLA(TM) PLATFORM AND ITS EXISTING IDYLLA(TM) ONCOLOGY ASSAY MENU TO COVANCE'S CUSTOMER BASE.  Full Article

Biocartis FY Total Operating Income Up At 28.7 Million Euros
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - BIOCARTIS GROUP NV ::FY TOTAL OPERATING INCOME: PRODUCT REVENUES INCREASED YEAR-OVER-YEAR WITH 46% TO EUR 18.8M.FY CASH POSITION: CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 64M AS PER 31 DECEMBER 2018.FY NET LOSS EUR 48.2 MILLION VERSUS LOSS OF EUR 42.0 MILLION YEAR AGO.FY TOTAL OPERATING INCOME EUR 28.7 MILLION VERSUS EUR 23.1 MILLION YEAR AGO.TARGETED CASH POSITION IN THE RANGE OF EUR 55M - EUR 65M BY 2019 YEAR END.TARGETING A COMMERCIAL VOLUME OF 210K-225K IDYLLA CARTRIDGES IN 2019, REPRESENTING A YEAR-OVER-YEAR INCREASE OF AROUND 60%-70%.TARGETING AN INSTALLED BASE GROWTH IN 2019 OF 350 NEW INSTRUMENT PLACEMENTS, BRINGING THE TOTAL INSTALLED BASE TO OVER 1,300 IDYLLA INSTRUMENTS BY YEAR-END.  Full Article

Biocartis Successfully Raises 55.50 Million Euros
Thursday, 24 Jan 2019 

Jan 23 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS SUCCESSFULLY RAISES EUR 55.50 MILLION.RAISED EUR 55.50 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING OF 5,000,000 NEW SHARES.  Full Article

Biocartis Cash Position At 64 Million Euros As Per December 31
Monday, 7 Jan 2019 

Jan 7 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS ANNOUNCES ACHIEVING ITS 2018 KEY BUSINESS OBJECTIVES.CASH POSITION - AS PER 31 DECEMBER 2018, BIOCARTIS' CASH POSITION AMOUNTED TO EUR 64M (NON-AUDITED NUMBER) VERSUS LATEST GUIDANCE OF AROUND EUR 55M..  Full Article

Biocartis Group And Nichirei Bioscience Announce Collaboration
Monday, 7 Jan 2019 

Jan 7 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND NICHIREI BIOSCIENCE ANNOUNCE COMMERCIALIZATION COLLABORATION FOR JAPANESE MARKET.SIGNED AGREEMENT WITH NICHIREI BIOSCIENCE FOR PRODUCT REGISTRATION AND EXCLUSIVE DISTRIBUTION OF BIOCARTIS' MOLECULAR DIAGNOSTIC (MDX) ONCOLOGY TESTS IN JAPAN.NICHIREI BIOSCIENCE WILL SEEK REGULATORY APPROVAL OF IDYLLA MDX ONCOLOGY TESTS WITH JAPANESE MINISTRY OF HEALTH, LABOR AND WELFARE.  Full Article

Genomic Health and Biocartis expand collaboration to urology with the development of an idylla oncotype dx genomic prostate score test
Tuesday, 4 Dec 2018 

Dec 3 (Reuters) - Biocartis Group NV ::GENOMIC HEALTH AND BIOCARTIS EXPAND COLLABORATION TO UROLOGY WITH THE DEVELOPMENT OF AN IDYLLA ONCOTYPE DX GENOMIC PROSTATE SCORE TEST.GENOMIC HEALTH - AS PART OF AGREEMENT, CO WILL MAKE A PAYMENT OF EUR 2.5 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q4 OF 2018.  Full Article

Biocartis Group And AstraZeneca Enter Into Agreement Aimed At Faster Lung Cancer Biomarker Results
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND ASTRAZENECA ENTER INTO AGREEMENT AIMED AT FASTER LUNG CANCER BIOMARKER RESULTS.PROSPECTIVE LUNG CANCER STUDY WITH IDYLLA(TM) EGFR MUTATION TEST (CE-IVD) WILL BE CONDUCTED IN SELECTED EUROPEAN COUNTRIES..STUDY IS AIMED AT DEMONSTRATING HOW UNIQUE FEATURES OF IDYLLA(TM) PLATFORM CAN OVERCOME CURRENT COMPLEXITY AND LONG TURNAROUND TIME FOR LUNG CANCER PATIENTS.STUDY WILL BE INITIATED AT MORE THAN A DOZEN SITES IN BELGIUM, FRANCE, GERMANY AND ITALY..  Full Article

Biocartis Group Announces Positive Study Results On Idylla Msi And Ras Liquid Biopsy Tests
Friday, 19 Oct 2018 

Oct 19 (Reuters) - BIOCARTIS GROUP NV ::RESULTS OF STUDY SHOWED IDYLLA(TM) LIQUID BIOPSY CTRAS-BRAF TESTS CAN PREDICT TREATMENT OUTCOME IN PATIENTS WITH MCRC.SECOND STUDY REVEALED POSITIVE PERFORMANCE OF PROTOTYPE IDYLLA(TM) MSI TEST BASED ON CONCORDANCE COMPARED TO OTHER TESTING METHODS FREQUENTLY USED.CONCORDANCE OF 98.7% WAS ACHIEVED WITH PROMEGA MSI ANALYSIS SYSTEM AND A CONCORDANCE OF 97.6% WITH IMMUNOHISTOCHEMICAL (IHC) ANALYSIS.SECOND STUDY DEMONSTRATES ROBUSTNESS OF IDYLLA(TM) MSI ASSAY, WHICH PROVIDES INFORMATION ON MSI STATUS OF TUMOR IN RAPID AND EASY WAY.THE STUDIES ON IDYLLA(TM) MSI AND RAS LIQUID BIOPSY TESTS TO BE PRESENTED AT ESMO CONGRESS.  Full Article